الإحصائيات الأساسية
| LEI | 529900PLC55DUQO4CR76 |
| CIK | 1325879 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to AVEO Pharmaceuticals Inc
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| January 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-34655 AVEO Pharmaceuticals, Inc. (Exact name of registrant as specified |
|
| January 19, 2023 |
Exhibit 99.1 LG Chem Completes Acquisition of AVEO Oncology AVEO to Become the U.S. Foundation for LG Chem Life Sciences’ Oncology Division SEOUL, South Korea, January 20, 2023 — LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology (“AVEO”), a commercial stage, oncology-focused biopharmaceutical company committed to d |
|
| January 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2023 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 19, 2023 |
As filed with the Securities and Exchange Commission on January 19, 2023 As filed with the Securities and Exchange Commission on January 19, 2023 Registration No. |
|
| January 19, 2023 |
As filed with the Securities and Exchange Commission on January 19, 2023 As filed with the Securities and Exchange Commission on January 19, 2023 Registration No. |
|
| January 19, 2023 |
As filed with the Securities and Exchange Commission on January 19, 2023 As filed with the Securities and Exchange Commission on January 19, 2023 Registration No. |
|
| January 19, 2023 |
As filed with the Securities and Exchange Commission on January 19, 2023 As filed with the Securities and Exchange Commission on January 19, 2023 Registration No. |
|
| January 19, 2023 |
As filed with the Securities and Exchange Commission on January 19, 2023 As filed with the Securities and Exchange Commission on January 19, 2023 Registration No. |
|
| January 19, 2023 |
Amended and Restated Bylaws of AVEO Pharmaceuticals, Inc. Exhibit 3.2 BYLAWS OF AVEO PHARMACEUTICALS, INC. (the “Corporation”) Article I - Stockholders 1. Annual Meeting. The annual meeting of stockholders shall be held for the election of directors each year at such place, date and time as shall be designated by the Board of Directors of the Corporation (the “Board of Directors”). Any other proper business may be transacted at the annual meeting. If no |
|
| January 19, 2023 |
Amended and Restated Certificate of Incorporation of AVEO Pharmaceuticals, Inc. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AVEO PHARMACEUTICALS, INC. ARTICLE I The name of the corporation is AVEO Pharmaceuticals, Inc. (the “Corporation”). ARTICLE II The address of the Corporation’s registered office in the State of Delaware is The Corporation Trust Company, 1209 Orange Street, in the City of Wilmington, County of New Castle, Delaware 19801. The name of t |
|
| January 19, 2023 |
As filed with the Securities and Exchange Commission on January 19, 2023 As filed with the Securities and Exchange Commission on January 19, 2023 Registration No. |
|
| January 19, 2023 |
As filed with the Securities and Exchange Commission on January 19, 2023 As filed with the Securities and Exchange Commission on January 19, 2023 Registration No. |
|
| January 19, 2023 |
As filed with the Securities and Exchange Commission on January 19, 2023 As filed with the Securities and Exchange Commission on January 19, 2023 Registration No. |
|
| January 19, 2023 |
As filed with the Securities and Exchange Commission on January 19, 2023 As filed with the Securities and Exchange Commission on January 19, 2023 Registration No. |
|
| January 19, 2023 |
As filed with the Securities and Exchange Commission on January 19, 2023 As filed with the Securities and Exchange Commission on January 19, 2023 Registration No. |
|
| January 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2023 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 5, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2023 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| December 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| December 20, 2022 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| December 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| December 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 AVEO Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34655 04-3581650 (State or other jurisdiction of incorporation) (Commis |
|
| November 25, 2022 |
DEFM14A 1 d407975ddefm14a.htm DEFM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the C |
|
| November 15, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) AVEO Pharmaceuticals, Inc. |
|
| November 15, 2022 |
PREM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 7, 2022 |
AVEO Oncology Reports Third Quarter 2022 Financial Results – Total Q3 2022 Net Revenue of $30. |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q RL DEFA14A: Additional proxy soliciting materials - definitive.fromPatent rights UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF |
|
| November 1, 2022 |
Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Aveo Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 053588109 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842 |
|
| October 20, 2022 |
AVEO / AVEO Pharmaceuticals, Inc. / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 2 Under the Securities Exchange Act of 1934 AVEO PHARMACEUTICALS INC (Name of Issuer) Common Stock (Title of Class of Securities) 053588307 (CUSIP Number) October 16, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| October 18, 2022 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2022 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Co |
|
| October 18, 2022 |
LG Chem to Acquire AVEO Oncology for $15.00 Per Share in Cash Exhibit 99.1 FOR IMMEDIATE RELEASE LG Chem to Acquire AVEO Oncology for $15.00 Per Share in Cash ? Acquisition Provides LG Chem?s Life Sciences Division a Commercial Footprint in the U.S., Diversifies its Pipeline with a Broad Range of Oncology Therapies and Accelerates LG Chem?s Efforts to Deliver Continued Growth ? AVEO Will Have Enhanced Ability to Deliver on its Mission to Improve the Lives of |
|
| October 18, 2022 |
DEFA14A 1 d410341ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| October 18, 2022 |
Execution Version CONFIDENTIAL Exhibit 2.1 AGREEMENT AND PLAN OF MERGER dated as of October 18, 2022 among AVEO PHARMACEUTICALS, INC., LG CHEM, LTD. and ACACIA ACQUISITION SUB, INC. TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions 1 Section 1.02 Other Definitional and Interpretative Provisions 13 ARTICLE 2 THE MERGER 14 Section 2.01 The Merger 14 Section 2.02 Conversion of S |
|
| October 18, 2022 |
Second Amended and Restated Bylaws of AVEO Pharmaceuticals, Inc, as amended Exhibit 3.1 SECOND AMENDED AND RESTATED BY-LAWS OF AVEO PHARMACEUTICALS, INC. TABLE OF CONTENTS ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 1 1.6 Quorum 1 1.7 Adjournments 1 1.8 Voting and Proxies 2 1.9 Action at Meeting. 2 1.10 Nomination of Directors. 2 1.11 Notice of Business at Annual Meetings 4 1.12 Cond |
|
| October 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2022 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 9, 2022 |
Passionately pursuing a better life for patients with cancer Corporate Overview August 2022 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. |
|
| August 9, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 5, 2022 |
Exhibit 107.1 Calculation of Filing Fee Table FORM S-8 (Form Type) AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Table 1?Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par |
|
| August 5, 2022 |
As filed with the Securities and Exchange Commission on August 4, 2022 As filed with the Securities and Exchange Commission on August 4, 2022 Registration No. |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q RL DEFA14A: Additional proxy soliciting materials - definitive.fromPatent rights UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|
| August 4, 2022 |
AVEO Oncology Reports Second Quarter 2022 Financial Results ? Total Q2 2022 Net Revenue of $25. |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| June 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 8, 2022 |
Certificate of Amendment of Restated Certificate of Incorporation of Registrant Delaware The First State Page 1 3444819 8100 Authentication: 203615775 SR# 20222645880 Date: 06-07-22 You may verify this certificate online at corp. |
|
| May 6, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 6, 2022 |
Passionately pursuing a better life for patients with cancer Corporate Overview May 2022 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 5, 2022 |
AVEO Oncology Reports First Quarter 2022 Financial Results ? Total Q1 2022 Net Revenue of $20. |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q DEFA14A: Additional proxy soliciting materials - definitive.fromPatent rights UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 F |
|
| April 26, 2022 |
DEFA14A 1 aveoproxydefa14a-2022combi.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permit |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 8, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2022 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 8, 2022 |
EXECUTION 30 WINTER STREET OFFICE LEASE 2 OFFICE LEASE BETWEEN TFC 30 WINTER LLC, a Massachusetts limited liability company, AS LANDLORD AND AVEO PHARMACEUTICALS, INC. |
|
| March 14, 2022 |
LICENSE AGREEMENT BY AND BETWEEN EUSA PHARMA (UK) LIMITED AND AVEO PHARMACEUTICALS, INC Dated: December 18, 2015 TABLE OF CONTENTS ARTICLE 1. |
|
| March 14, 2022 |
Subsidiaries of the Registrant SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Organization Percentage Ownership AVEO Pharma Limited United Kingdom 100% AVEO Securities Corporation Massachusetts 100% AVEO Pharma (Ireland) Limited Ireland 100% |
|
| March 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2022 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 14, 2022 |
Offer Letter by the Registrant to Jebediah Ledell, dated November 12, 2021 November 12, 2021 Jebediah Ledell 36 Village View Rd Westford, MA, 01886 Dear Jeb: It is with great pleasure that we extend you this offer of employment to join AVEO Pharmaceuticals, Inc. |
|
| March 14, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2022 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 14, 2022 |
Execution Version Conformed ? 3rd Amendment AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (as amended by that certain (i) First Amendment to Amended and Restated Loan and Security Agreement dated as of August 7, 2020 (the ?First Amendment?), (ii) Second Amendment to Amended and Restated Loan and Security Agreement dated as of February 1, 2021 (the ?Second Amendment?) and (iii) Third Amendment to Amended and Restated Loan and Security Agreement dated as of March 8, 2022 (the ?Third Amendment?)) is made and dated as of December 28, 2017 and is entered into by and between AVEO PHARMACEUTICALS, INC. |
|
| March 14, 2022 |
REVOCABLE TEMPORARY LICENSE AGREEMENT THIS REVOCABLE TEMPORARY LICENSE AGREEMENT (this ?License?) dated as of November 17, 2021 is entered into between TFC 30 Winter LLC, a Massachusetts limited liability company (?Licensor?), and AVEO Pharmaceuticals, Inc. |
|
| March 14, 2022 |
Form of Non-Competition and Non-Solicitation Agreement, dated March NON-COMPETITION AND NON-SOLICITATION AGREEMENT This Non-Competition and Non-Solicitation Agreement (the ?Agreement?) is made between AVEO Pharmaceuticals, Inc. |
|
| March 14, 2022 |
AVEO Oncology Reports Full Year and Fourth Quarter 2021 Financial Results ? Total 2021 Net Revenue of $42. |
|
| March 14, 2022 |
Restated Certificate of Incorporation of the Registrant, as amended Delaware The First State Page 1 3444819 8100X Authentication: 202854145 SR# 20220916489 Date: 03-08-22 You may verify this certificate online at corp. |
|
| March 14, 2022 |
Offer Letter by the Registrant to Michael Ferraresso, dated April 8, 2021 AVEO Pharmaceuticals, Inc. 30 Winter Street Boston, MA 02108 p. 857.400.0101 April 8, 2021 Michael Ferraresso 84 Naugus Road Marblehead, MA 01945 Dear Mike: It is with great pleasure that we present to you a promotion from your current position of SVP, Commercial Analytics & Business Development to Chief Commercial Officer. Position. Your new position will be Chief Commercial Officer, and you will |
|
| March 14, 2022 |
Passionately pursuing a better life for patients with cancer Corporate Overview March 2022 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. |
|
| March 14, 2022 |
SEVERANCE AND CHANGE IN CONTROL AGREEMENT THIS SEVERANCE AND CHANGE IN CONTROL AGREEMENT (the ?Agreement?), made this 10th day of March 2021 (the ?Effective Date?), is entered into by AVEO Pharmaceuticals, Inc. |
|
| March 14, 2022 |
SEVERANCE AND CHANGE IN CONTROL AGREEMENT . THIS SEVERANCE AND CHANGE IN CONTROL AGREEMENT (the "Agreement"), made this 15 day of November 2021 (the "Effective Date"), is entered into by AYEO Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 30 Winter Street Boston, MA 02108 (the "Company"), and Jebediah Ledell (the "Employee") with a address at 36 Village View |
|
| March 14, 2022 |
Executive Severance and Change in Control Plan AVEO Pharmaceuticals, Inc. Executive Severance and Change in Control Benefits Plan 1.Establishment of Plan. AVEO Pharmaceuticals, Inc., a Delaware corporation, hereby establishes an unfunded severance benefits plan (the ?Plan?) that is intended to be a welfare benefit plan within the meaning of Section 3(1) of ERISA. The Plan is in effect for Covered Employees who experience a Covered Termination |
|
| March 14, 2022 |
FIRST AMENDMENT TO SUBLEASE AGREEMENT 30 WINTER STREET Boston, Massachusetts This First Amendment to Sublease Agreement (this ?Agreement?) is dated as of November 17, 2021 (?Effective Date?) by and between Commonwealth Care Alliance, Inc. |
|
| March 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K fromPatent rights UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3 |
|
| February 11, 2022 |
AVEO / AVEO Pharmaceuticals, Inc. / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 AVEO PHARMACEUTICALS INC (Name of Issuer) Common Stock (Title of Class of Securities) 053588307 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| December 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2021 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 8, 2021 |
*9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents *9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34655 AVEO PHARMACEUTICALS, INC. |
|
| November 8, 2021 |
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. |
|
| November 8, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 8, 2021 |
Exhibit 99.1 AVEO Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update ? Total Q3 2021 Revenue of $15.2 Million Includes FOTIVDA? (tivozanib) U.S. Net Product Revenue of $14.3 Million ? ? Enrollment Open for Pivotal Phase 3 TiNivo-2 Clinical Trial of FOTIVDA? (tivozanib) in Combination with OPDIVO? (nivolumab) ? ? Ficlatuzumab and ERBITUX? (cetuximab) Granted Fast Tra |
|
| September 15, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 AVEO PHARMACEUTICALS INC (Name of Issuer) Common Stock (Title of Class of Securities) 053588307 (CUSIP Number) September 3, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed ? Rule 13d-1( |
|
| August 27, 2021 |
Exhibit 10.1 TRANSITION, SEPARATION, AND RELEASE OF CLAIMS AGREEMENT This Transition, Separation, and Release of Claims Agreement (the ?Agreement?) is made as of the Agreement Effective Date (as defined below) by and between Aveo Pharmaceuticals, Inc. (the ?Company?) and Michael N. Needle, M.D. (?Executive?) (together, the ?Parties?). WHEREAS, the Company and Executive are parties to the Severance |
|
| August 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2021 AVEO Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-34655 04-3581650 (State or other jurisdiction of incorporation) (Commission |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 5, 2021 |
EX-99.1 2 aveo-ex9916.htm EX-99.1 Exhibit 99.1 AVEO Oncology Reports Second Quarter 2021 Financial Results and Provides Business Update – Total 2Q 2021 Revenue of $7.6 Million Includes FOTIVDA® (tivozanib) U.S. Net Product Revenue of $6.7 Million – – Pivotal Phase 3 TiNivo-2 Trial of FOTIVDA in Combination with OPDIVO® (nivolumab) on Track to Initiate Enrollment in 3Q 2021 – – COVID-19 Related Man |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| July 16, 2021 |
FOTIVDA? (tivozanib) in Renal Cell Carcinoma July 16, 2021 Exhibit 99.1 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are fo |
|
| July 16, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2021 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 10, 2021 |
As filed with the Securities and Exchange Commission on June 10, 2021 As filed with the Securities and Exchange Commission on June 10, 2021 Registration No. |
|
| June 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2021 AVEO Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-34655 04-3581650 (State or other jurisdiction of incorporation) (Commission |
|
| June 9, 2021 |
AMENDMENT NO. 2 TO 2019 EQUITY INCENTIVE PLAN OF AVEO PHARMACEUTICALS, INC. Exhibit 99.1 AMENDMENT NO. 2 TO 2019 EQUITY INCENTIVE PLAN OF AVEO PHARMACEUTICALS, INC. The 2019 Equity Incentive Plan of Aveo Pharmaceuticals, Inc., as amended (the ?2019 Equity Incentive Plan?) is hereby further amended as follows: 1. Section 4(a)(1)(A) is hereby deleted in its entirety and the following is inserted in lieu thereof: ?4,500,000 shares of Common Stock.? Except as set forth above, |
|
| June 9, 2021 |
Exhibit 99.2 AMENDED AND RESTATED 2010 EMPLOYEE STOCK PURCHASE PLAN OF AVEO PHARMACEUTICALS, INC. AVEO PHARMACEUTICALS, INC. AMENDED AND RESTATED 2010 EMPLOYEE STOCK PURCHASE PLAN The purpose of this Plan is to provide eligible employees of AVEO Pharmaceuticals, Inc. (the ?Company?) and certain of its subsidiaries with opportunities to purchase shares of the Company?s common stock, $.001 par value |
|
| June 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2021 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 10, 2021 |
Clinical Trial Collaboration and Supply Agreement Exhibit 10.2 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. EXECUTION VERSION CONFIDENTIAL CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT This CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (the ?Agreement?) is ma |
|
| May 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 10, 2021 |
Exhibit 99.1 AVEO Oncology Reports First Quarter 2021 Financial Results and Provides Business Update ? U.S. Commercial Launch Underway with Fully Deployed Sales Force Following FDA Approval of FOTIVDA? (tivozanib) on March 10, 2021 ? ? FOTIVDA Net Product Revenue of $1.1 Million from Initial Distributor Orders in the Last Week of Q1; All Distributors Have Placed Reorders for Q2 ? ? Entered Clinica |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| May 10, 2021 |
, 2021, by and between the Registrant and Bristol-Myers Squibb Company Exhibit 10.3 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDMENT No. 1 to Clinical Trial Collaboration and Supply Agreement This Amendment No. 1 to Clinical Trial Collaboration and Supply Agreement (this ?Amendment |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ?Filed by a party other than the Registrant ? Check the appropriate box: ?Preliminary Proxy Statement ?Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ?Definitive Proxy Statement |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ?Filed by a party other than the Registrant ? Check the appropriate box: ?Preliminary Proxy Statement ?Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ?Definitive Proxy Statement |
|
| April 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2021 AVEO Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-34655 04-3581650 (State or other jurisdiction of incorporation) (Commission F |
|
| April 16, 2021 |
AVEO Announces Appointment of Kevin Cullen, M.D., to its Board of Directors EX-99.1 EXHIBIT 99.1 AVEO Announces Appointment of Kevin Cullen, M.D., to its Board of Directors BOSTON, Mass. – April 16, 2021 – AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced the appointment of Kevin J. Cullen, M.D., to the Company’s Board of Directors. A widely recognized clinical oncologist with a specialty in head and neck |
|
| April 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ?Filed by a party other than the Registrant ? Check the appropriate box: ?Preliminary Proxy Statement ?Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ?Definitive Proxy Statement |
|
| March 24, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-249982 PROSPECTUS SUPPLEMENT (To Prospectus dated November 18, 2020) 6,000,000 Shares Common Stock We are offering 6,000,000 shares of our common stock. Our common stock is listed on the Nasdaq Capital Market under the symbol ?AVEO.? The last reported sale price for our common stock on March 23, 2021 was $8.69 per share. This |
|
| March 24, 2021 |
Exhibit 1.1 AVEO PHARMACEUTICALS, INC. (a Delaware corporation) 6,000,000 Shares of Common Stock UNDERWRITING AGREEMENT March 23, 2021 SVB Leerink LLC Stifel, Nicolaus & Company, Incorporated as Representatives of the several Underwriters c/o SVB Leerink LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 c/o Stifel, Nicolaus & Company, Incorporated 787 Seventh Avenue, 11th Floor New Yo |
|
| March 24, 2021 |
AVEO Announces Pricing of $48.0 Million Public Offering of Common Stock EX-99.1 Exhibit 99.1 AVEO Announces Pricing of $48.0 Million Public Offering of Common Stock BOSTON, Mass. – March 23, 2021 — AVEO Oncology (Nasdaq: AVEO) today announced that it has priced its previously announced underwritten public offering of 6,000,000 shares of its common stock at a price to the public of $8.00 per share. The gross proceeds to AVEO from the offering are expected to be $48.0 m |
|
| March 24, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2021 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 22, 2021 |
SUBJECT TO COMPLETION, DATED MARCH 22, 2021 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-249982 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell |
|
| March 16, 2021 |
en UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2020 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34655 AVEO PHARM |
|
| March 16, 2021 |
Exhibit 99.1 AVEO Oncology Reports Full Year 2020 Financial Results and Provides Business Update – FOTIVDA® (tivozanib) Approved for Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma Following Two or More Prior Systemic Therapies; AVEO Plans to Make FOTIVDA Available to Patients in the U.S. by March 31, 2021 – - Entered Clinical Trial Collaboration and Supply Agreement with |
|
| March 16, 2021 |
Execution Copy Exhibit 10.27 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. OPTION AND LICENSE AGREEMENT BY AND BETWEEN AVEO PHARMACEUTICALS, INC. AND BIOGEN IDEC INTERNATIONAL GMBH OPTION AND LICENSE AGREEMENT This Opt |
|
| March 16, 2021 |
Restated Certificate of Incorporation of the Registrant, as amended Exhibit 3.1 Delaware Page 1 The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED ARE TRUE AND CORRECT COPIES OF ALL DOCUMENTS FILED FROM AND INCLUDING THE RESTATED CERTIFICATE OR A MERGER WITH A RESTATED CERTIFICATE ATTACHED OF ?AVEO PHARMACEUTICALS, INC.? AS RECEIVED AND FILED IN THIS OFFICE. THE FOLLOWING DOCUMENTS HAVE BEEN CERTIFIED |
|
| March 16, 2021 |
Subsidiaries of the Registrant EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Organization Percentage Ownership AVEO Pharma Limited United Kingdom 100% AVEO Securities Corporation Massachusetts 100% AVEO Pharma (Ireland) Limited Ireland 100% |
|
| March 16, 2021 |
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. |
|
| March 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2021 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 15, 2021 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2021 AVEO Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-34655 04-3581650 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 10, 2021 |
EX-99.1 Exhibit 99.1 AVEO Oncology Announces U.S. FDA Approval of FOTIVDA® (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma - FOTIVDA is the First Therapy Approved for Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma Following Two or More Prior Systemic Therapies – - AVEO Plans to Make FOTIVDA Available to Patients in |
|
| March 10, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2021 AVEO Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-34655 04-3581650 (State or other jurisdiction of incorporation) (Commission F |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* AVEO Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 053588307 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2021 AVEO Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-34655 04-3581650 (State or other jurisdiction of incorporation) (Commissio |
|
| February 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2021 AVEO Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-34655 04-3581650 (State or other jurisdiction of incorporation) (Commission |
|
| February 2, 2021 |
EX-10.1 Exhibit 10.1 EXECUTION VERSION SECOND AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT This SECOND AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Amendment”) is dated as of February 1, 2021 and is entered into by and among (a) AVEO PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), (b) the several banks and other financial institutions or entitie |
|
| January 29, 2021 |
EX-10.1 Exhibit 10.1 SEPARATION AND RELEASE OF CLAIMS AGREEMENT This Separation and Release of Claims Agreement (the “Agreement”) is made as of the Agreement Effective Date (as defined below) by and between Aveo Pharmaceuticals, Inc. (the “Company”) and Karuna Rubin (“Executive”) (together, the “Parties”). WHEREAS, the Company and Executive are parties to the Employment Agreement dated as of June |
|
| January 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2021 AVEO Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-34655 04-3581650 (State or other jurisdiction of incorporation) (Commission |
|
| January 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2021 AVEO Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-34655 04-3581650 (State or other jurisdiction of incorporation) (Commission |
|
| January 12, 2021 |
EX-99.1 Exhibit 99.1 AVEO Oncology Highlights Recent Progress and 2021 Outlook – Commercial Readiness Nearing Completion in Support of Potential Tivozanib U.S. Launch – – Updated IP Strategy Offers Potential for Tivozanib Patent Term Extension to November 2028 – – Corinne D. Epperly, MD, MPH, Appointed to Board of Directors – – Phase 2 Open Label Randomized Study of Ficlatuzumab in HNSCC Enrollmen |
|
| January 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2021 AVEO Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) Delaware 001-34655 04-3581650 (State or other jurisdiction of incorporation) (Commission |
|
| November 20, 2020 |
S-8 As filed with the Securities and Exchange Commission on November 19, 2020 Registration No. |
|
| November 16, 2020 |
CORRESP November 16, 2020 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Tim Buchmiller Re: AVEO Pharmaceuticals, Inc. |
|
| November 9, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2020 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 9, 2020 |
Exhibit 99.1 AVEO Oncology Reports Third Quarter 2020 Financial Results and Provides Business Update - U.S. Commercial Launch Preparations Underway Supporting the Tivozanib PDUFA Target Action Date of March 31, 2021 – - Ficlatuzumab Worldwide Rights Regained; Final Results from Open Label Randomized Phase 2 HNSCC Study and Plans for Pivotal Program Expected in the Middle of 2021 – - AV-380 IND Sub |
|
| November 9, 2020 |
Table of Contents As filed with the Securities and Exchange Commission on November 9, 2020 Registration No. |
|
| November 9, 2020 |
Exhibit 4.7 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE |
|
| November 9, 2020 |
Exhibit 4.4 AVEO PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) In |
|
| November 9, 2020 |
Exhibit 4.6 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE |
|
| November 9, 2020 |
Form of Subordinated Indenture Exhibit 4.5 AVEO PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 31 |
|
| November 9, 2020 |
Exhibit 1.3 AMENDMENT NO. 1 TO SALES AGREEMENT November 9, 2020 SVB LEERINK LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 Ladies and Gentlemen: This Amendment No. 1 to Sales Agreement (this ?Amendment?) is entered into as of the date first written above by AVEO Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and SVB Leerink LLC (formerly known as Leerink Partners LL |
|
| November 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| September 8, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2020 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| September 8, 2020 |
EX-99.1 Exhibit 99.1 AVEO Oncology Regains Full Global Rights to Ficlatuzumab Announces Decision to Fund Clinical Manufacture of Ficlatuzumab for Potential Phase 3 Study and Update to Biodesix Partnership No Change to AVEO Cash Runway Guidance BOSTON, Mass. – September 8, 2020 – AVEO Oncology (Nasdaq: AVEO) today announced that it has regained full global rights to ficlatuzumab, AVEO’s potent hepa |
|
| August 10, 2020 |
Exhibit 99.1 AVEO Oncology Reports Second Quarter 2020 Financial Results and Provides Business Update - NDA Filing Accepted by U.S. FDA for Tivozanib as a Treatment of Relapsed or Refractory Renal Cell Carcinoma; Assigned PDUFA Target Action Date of March 31, 2021 – - Preparations Underway to Support Potential Commercial Launch of Tivozanib in the U.S.; New Debt and Equity Financings, Partnership |
|
| August 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2020 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| August 10, 2020 |
Exhibit 10.1 Execution Version First AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT This First Amendment to Amended and Restated Loan and Security Agreement (this “Amendment”) is dated as of August 7, 2020 and is entered into by and among (a) AVEO PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), (b) the several banks and other financial institutions or entities from time |
|
| July 6, 2020 |
EX-99.1 Passionately pursuing a better life for patients with cancer July 2020 Pipeline Overview Exhibit 99.1 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, |
|
| July 6, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2020 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 29, 2020 |
AVEO / AVEO Pharmaceuticals, Inc. / Cormorant Asset Management, LLC Passive Investment SC 13G 1 schedule13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AVEO Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 053588307 (CUSIP Number) June 17, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| June 29, 2020 |
Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of June 29, 2020, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Asset Management, LP and Bihua Chen (collectively, the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D and/o |
|
| June 29, 2020 |
Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of June 29, 2020, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Asset Management, LP and Bihua Chen (collectively, the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D and/o |
|
| June 29, 2020 |
AVEO / AVEO Pharmaceuticals, Inc. / Cormorant Asset Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AVEO Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 053588307 (CUSIP Number) June 17, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| June 24, 2020 |
Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Aveo Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 053588109 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842 |
|
| June 19, 2020 |
AVEO / AVEO Pharmaceuticals, Inc. / Flynn James E Passive Investment SC 13G 1 e619713sc13g-aveo.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. ) * AVEO Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 053588307 (CUSIP Number) June 19, 202 |
|
| June 17, 2020 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-221837 PROSPECTUS SUPPLEMENT (To Prospectus dated December 15, 2017) 8,500,000 Shares Common Stock We are offering 8,500,000 shares of our common stock. Our common stock is listed on the Nasdaq Capital Market under the symbol “AVEO.” The last reported sale price for our common stock on June 16, 2020 was $6.25 per share. |
|
| June 17, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2020 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 17, 2020 |
AVEO Announces Pricing of $44.6 Million Public Offering of Common Stock EX-99.1 Exhibit 99.1 AVEO Announces Pricing of $44.6 Million Public Offering of Common Stock BOSTON, Mass. – June 16, 2020 — AVEO Oncology (Nasdaq: AVEO) today announced that it has priced its previously announced underwritten public offering of 8,500,000 shares of its common stock at a price to the public of $5.25 per share. The gross proceeds to AVEO from the offering are expected to be approxim |
|
| June 17, 2020 |
EX-1.1 Exhibit 1.1 AVEO PHARMACEUTICALS, INC. (a Delaware corporation) 8,500,000 Shares of Common Stock UNDERWRITING AGREEMENT June 16, 2020 SVB Leerink LLC Stifel, Nicolaus & Company, Incorporated as Representatives of the several Underwriters c/o SVB Leerink LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 c/o Stifel, Nicolaus & Company, Incorporated 787 Seventh Avenue, 11th Floor |
|
| June 15, 2020 |
SUBJECT TO COMPLETION, DATED JUNE 15, 2020 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-221837 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell |
|
| June 15, 2020 |
Results of Operations and Financial Condition, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2020 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 10, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2020 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commi |
|
| June 10, 2020 |
AMENDMENT NO. 1 TO 2019 EQUITY INCENTIVE PLAN OF AVEO PHARMACEUTICALS, INC. EX-99.1 Exhibit 99.1 AMENDMENT NO. 1 TO 2019 EQUITY INCENTIVE PLAN OF AVEO PHARMACEUTICALS, INC. The 2019 Equity Incentive Plan of Aveo Pharmaceuticals, Inc. (the “2019 Equity Incentive Plan”) is hereby amended as follows: 1. Section 4(a)(1)(A) is hereby deleted in its entirety and the following is inserted in lieu thereof: “2,300,000 shares of Common Stock.” 2. Section 4(b) is hereby deleted in i |
|
| June 1, 2020 |
Financial Statements and Exhibits, Other Events 8-K 1 d904464d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2020 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incor |
|
| June 1, 2020 |
EX-99.1 Exhibit 99.1 AVEO Oncology Announces FDA Acceptance for Filing of a New Drug Application for Tivozanib as a Treatment of Relapsed or Refractory Renal Cell Carcinoma - Tivozanib assigned PDUFA target action date of March 31, 2021; FDA indicates that it does not currently plan to convene an ODAC - BOSTON, Mass. – June 1, 2020 – AVEO Oncology (NASDAQ: AVEO) today announced that the U.S. Food |
|
| May 29, 2020 |
EX-99.3 Exhibit 99.3 AVEO Oncology Announces Phase 1b/2 DEDUCTIVE Study of FOTIVDA® (tivozanib) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma Advances to Phase 2 BOSTON, Mass. – May 29, 2020 – AVEO Oncology (NASDAQ: AVEO) today announced that the Phase 1b/2 DEDUCTIVE clinical trial evaluating FOTIVDA® (tivozanib), the Company’s once-daily, po |
|
| May 29, 2020 |
EX-99.2 Exhibit 99.2 AVEO Oncology Announces TIVO-3 Final Overall Survival Results Featured at ASCO 2020 Virtual Scientific Program and Submitted to U.S. FDA as Part of NDA Filing - Final OS Hazard Ratio Improves to 0.97 - - Company to Host Conference Call Today at 8:30 am Eastern Time - BOSTON, Mass. – May 29, 2020 – AVEO Oncology (NASDAQ: AVEO) today announced the presentation of results from th |
|
| May 29, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events 8-K 1 d889663d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2020 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incor |
|
| May 29, 2020 |
EX-99.1 Passionately pursuing a better life for patients with cancer TIVO-3 Overall Survival Update Conference Call May 29, 2020 Exhibit 99.1 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than |
|
| May 27, 2020 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| May 27, 2020 |
AVEO Announces Change to Virtual Annual Meeting of Stockholders EX-99.1 Exhibit 99.1 AVEO Announces Change to Virtual Annual Meeting of Stockholders BOSTON, Mass. – May 27, 2020 – AVEO Oncology (NASDAQ: AVEO) today announced that due to the public health impact of the novel coronavirus (COVID-19) outbreak and governmental restrictions limiting the number of people who may gather together, and to support the health and well-being of its stockholders, employees |
|
| May 27, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2020 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 30, 2020 |
AVEO Oncology Reports First Quarter 2020 Financial Results and Provides Business Update Exhibit 99.1 AVEO Oncology Reports First Quarter 2020 Financial Results and Provides Business Update BOSTON, Mass. – April 30, 2020 – AVEO Oncology (NASDAQ: AVEO) today reported financial results for the first quarter ended March 31, 2020 and provided a business update. “Our recent submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval |
|
| April 30, 2020 |
Sublease, dated March 5, 2020, by and between the Registrant and Commonwealth Care Alliance, Inc. Exhibit 10.2 SUBLEASE AGREEMENT THIS SUBLEASE AGREEMENT made as of the 5th day of March, 2020 (the “Effective Date”) by and between Commonwealth Care Alliance, Inc. a Massachusetts not-for-profit corporation (“Sublandlord”), and AVEO Pharmaceuticals, Inc., a Delaware corporation (“Subtenant”); WHEREAS, Sublandlord is the tenant under that certain Lease dated January 26, 2007 (the “Lease”), as amen |
|
| April 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| April 30, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2020 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒Definitive Proxy Statemen |
|
| April 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐Definitive Proxy Statemen |
|
| March 16, 2020 |
en UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34655 AVEO PHARM |
|
| March 16, 2020 |
Subsidiaries of the Registrant EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Organization Percentage Ownership AVEO Pharma Limited United Kingdom 100% AVEO Securities Corporation Massachusetts 100% AVEO Pharma (Ireland) Limited Ireland 100% |
|
| March 16, 2020 |
AVEO Oncology Reports Full Year 2019 Financial Results and Provides Business Update Exhibit 99.1 AVEO Oncology Reports Full Year 2019 Financial Results and Provides Business Update CAMBRIDGE, Mass.– March 16, 2020 – AVEO Oncology (NASDAQ: AVEO) today reported financial results for the full year ended December 31, 2019 and provided a business update. “The coming months will be an important period for AVEO, with filing of a New Drug Application (NDA) for tivozanib as a treatment fo |
|
| March 16, 2020 |
EXHIBIT 10.17 SEVERANCE AND CHANGE IN CONTROL AGREEMENT THIS SEVERANCE AND CHANGE IN CONTROL AGREEMENT (the “Agreement”), made this 6th day of January 2020 (the “Effective Date”), is entered into by AVEO Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 1 Broadway 14th Floor, Cambridge, MA 02142 (the “Company”), and Erick Lucera (the “Employee”). WHEREAS, the Co |
|
| March 16, 2020 |
Description of Registered Securities EXHIBIT 4.5 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of registered securities of AVEO Pharmaceuticals, Inc. (“us,” “our,” “we” or the “Company”) is intended as a summary only and therefore is not a complete description. This description is based upon, and is qualified by reference to, our restated certificate of incorporation, as amended, |
|
| March 16, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2020 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 16, 2020 |
Offer Letter by and between the Registrant and Erick Lucera, dated December 12, 2019 AVEO Pharmaceuticals, Inc. 1 Broadway, 14th Floor Cambridge, MA 02142 p. 617.588.1960 EXHIBIT 10.16 December 12, 2019 Erick Lucera [address] [address] Dear Erick: It is with great pleasure that we extend you this offer of employment to join AVEO Pharmaceuticals. The following letter sets forth the proposed terms and conditions of your offer of employment.Position. Your position will be Chief Finan |
|
| March 16, 2020 |
Specimen Stock Certificate evidencing the shares of common stock Exhibit 4.1 AVEO ONCOLOGY PO BOX 505006, Louisville, KY 40233-5006 MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 CUSIP/IDENTIFIER XXXXXX XX X Holder ID XXXXXXXXXX Insurance Value 1,000,000.00 Number of Shares 123456 DTC 12345678 123456789012345 Certificate Numbers Num/No. Denom. Total 1234567890/1234567890 1 1 1 1234567890/1234567890 2 2 2 1234567890/1234567890 3 3 3 1234567890/12345678 |
|
| February 19, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2020 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 19, 2020 |
AVEO Announces Effectiveness of 1-for-10 Reverse Stock Split EX-99.1 Exhibit 99.1 AVEO Announces Effectiveness of 1-for-10 Reverse Stock Split CAMBRIDGE, Mass. – February 19, 2020 – AVEO Oncology (NASDAQ: AVEO) today announced that it will effect a 1-for-10 reverse stock split of its common stock that will be effective as of 5:00 p.m. Eastern Time today, February 19, 2020. AVEO’s common stock will begin trading on the Nasdaq Capital Market on a split-adjust |
|
| February 19, 2020 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF AVEO PHARMACEUTICALS, INC. AVEO Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as follows: 1. The current name of the Corporation is |
|
| February 13, 2020 |
Other Events, Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2020 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 4, 2020 |
AVEO / AVEO Pharmaceuticals, Inc. DEFA14A - - DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, fo |
|
| January 24, 2020 |
AVEO / AVEO Pharmaceuticals, Inc. DEFA14A - - DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, fo |
|
| January 8, 2020 |
AVEO / AVEO Pharmaceuticals, Inc. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒Definitive Proxy Statemen |
|
| January 6, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 25, 2019 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 16, 2019 |
AVEO / AVEO Pharmaceuticals, Inc. PRE 14A - - PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐Definitive Proxy Statemen |
|
| November 19, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2019 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 12, 2019 |
AVEO / AVEO Pharmaceuticals, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| November 12, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2019 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 12, 2019 |
AVEO Reports Third Quarter 2019 Financial Results and Provides Business Update Exhibit 99.1 AVEO Reports Third Quarter 2019 Financial Results and Provides Business Update CAMBRIDGE, Mass. – November 12, 2019 – AVEO Oncology (NASDAQ: AVEO) today reported financial results for the third quarter ended September 30, 2019 and provided a business update. “This quarter we have made meaningful progress toward our goal of bringing effective and better tolerated therapies to patients |
|
| November 5, 2019 |
EX-99.1 AVEO Overview November 2019 Cautionary Note Regarding Forward-Looking Statements Multiple Potential Opportunities for Value Creation Financial Highlights FOTIVDA® (tivozanib) TIVO-3 Pivotal Phase 3 Study Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor TIVO-3: Study Design TIVO-3: Superior PFS and ORR* Progression-Free Survival – Key Subgroups* Durable Disease Control with Tivozanib ( |
|
| November 5, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 d816002d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2019 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction |
|
| October 3, 2019 |
EX-99.1 AVEO Overview October 2019 Exhibit 99 .1 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statement |
|
| October 3, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2019 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Com |
|
| September 27, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2019 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) ( |
|
| September 17, 2019 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2019 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) ( |
|
| September 12, 2019 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2019 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) ( |
|
| September 10, 2019 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2019 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) ( |
|
| September 10, 2019 |
EX-99.2 AVEO Overview September 2019 Exhibit 99.2 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statemen |
|
| September 10, 2019 |
EX-99.1 Exhibit 99.1 AVEO Oncology Announces Updated Overall Survival Hazard Ratio of 0.99 in Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma - 20 Patients Remain Progression Free on Tivozanib Arm vs. 2 on Sorafenib Arm - - Company Plans to Discuss Updated Results with FDA - - AVEO to Host Conference Call Today at 8:00 am Eastern Time - CAMBRIDGE, Mass. – September 10, 2019 – AVEO Oncolo |
|
| August 27, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2019 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Com |
|
| August 8, 2019 |
AVEO Reports Second Quarter 2019 Financial Results and Provides Business Update Exhibit 99.1 AVEO Reports Second Quarter 2019 Financial Results and Provides Business Update CAMBRIDGE, Mass. – August 8, 2019 – AVEO Oncology (NASDAQ: AVEO) today reported financial results for the second quarter ended June 30, 2019 and provided a business update. “As we move toward reporting more mature interim overall survival (OS) results from our TIVO-3 study of tivozanib in advanced kidney c |
|
| August 8, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2019 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 8, 2019 |
AVEO / AVEO Pharmaceuticals, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| August 8, 2019 |
Exhibit 3.1 State of Delaware Secretary of State Division of Corporations Delivered 07:50 AM 03/17/2010 FILED 08:00 AM 03/17/2010 SRV 100286912 – 3444819 FILE RESTATED CERTIFICATE OF INCORPORATION OF AVEO PHARMACEUTICALS, INC. (originally incorporated on October 19, 2001 under the name GenPath Pharmaceuticals, Inc.) FIRST: The name of the Corporation is Aveo Pharmaceuticals, Inc. SECOND: The addre |
|
| August 1, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2019 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Comm |
|
| August 1, 2019 |
EX-10.1 Exhibit 10.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. AMENDMENT TO LICENSE AGREEMENT THIS AMENDMENT TO the December 21, 2006 LICENSE AGREEMENT (this “Amendment”) is made and entered into this 1st day of August, 2 |
|
| June 13, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2019 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 13, 2019 |
Certificate of Amendment to Restated Certificate of Incorporation of AVEO Pharmaceuticals, Inc. EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF AVEO PHARMACEUTICALS, INC. AVEO Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as follows: 1. The name of the Corporation is AVEO Ph |
|
| May 31, 2019 |
AVEO / AVEO Pharmaceuticals, Inc. DEFA14A - - DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, fo |
|
| May 9, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2019 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 9, 2019 |
AVEO Reports First Quarter 2019 Financial Results and Provides Business Update Exhibit 99.1 AVEO Reports First Quarter 2019 Financial Results and Provides Business Update CAMBRIDGE, Mass. – May 9, 2019 – AVEO Oncology (NASDAQ: AVEO) today reported financial results for the first quarter ended March 31, 2019 and provided a business update. “With a successful recent equity offering, together with the triggering of a FOTIVDA® (tivozanib) milestone from EUSA, AVEO’s strengthened |
|
| May 9, 2019 |
AVEO / AVEO Pharmaceuticals, Inc. 10-Q Quarterly Report 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| April 30, 2019 |
AVEO / AVEO Pharmaceuticals, Inc. DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐Definitive Proxy Statemen |
|
| April 30, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒Definitive Proxy Statemen |
|
| April 30, 2019 |
AVEO / AVEO Pharmaceuticals, Inc. 10-K/A Annual Report 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2018 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3 |
|
| April 30, 2019 |
EXHIBIT 10.36 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. AGREEMENT Agreement (the “Agreement”), dated December 18, 2018 (the “Agreement Effective Date”), by and between Novartis International Pharmaceutical Ltd. (“Novartis |
|
| April 19, 2019 |
AVEO / AVEO Pharmaceuticals, Inc. PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐Definitive Proxy Statemen |
|
| April 17, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Aveo Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 053588109 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, |
|
| April 4, 2019 |
AVEO Pharmaceuticals, Inc. Announces Pricing of $25 Million Underwritten Public Offering EX-99.1 Exhibit 99.1 AVEO Pharmaceuticals, Inc. Announces Pricing of $25 Million Underwritten Public Offering CAMBRIDGE, Mass. – April 3, 2019 – AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) (“AVEO” or the “Company”), a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs, today announced the pricing of its previously announced underwritten public |
|
| April 4, 2019 |
EX-4.1 Exhibit 4.1 Form of Warrant COMMON STOCK PURCHASE WARRANT AVEO PHARMACEUTICALS, INC. Warrant Shares: Issue Date: , 2019 Initial Exercise Date: , 2019 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time o |
|
| April 4, 2019 |
EX-1.1 Exhibit 1.1 21,739,131 Shares of Common Stock Warrants to Purchase up to 21,739,131 Shares of Common Stock AVEO PHARMACEUTICALS, INC. PURCHASE AGREEMENT April 3, 2019 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: AVEO Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to sell to H.C. Wainwright & Co., LLC, as underwriter (the |
|
| April 4, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2019 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 4, 2019 |
424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-221837 Prospectus Supplement (To Prospectus dated December 15, 2017) AVEO PHARMACEUTICALS, INC. 21,739,131 Shares of Common Stock Warrants to Purchase up to 21,739,131 Shares of Common Stock AVEO Pharmaceuticals, Inc. is offering 21,739,131 shares of common stock and warrants to purchase up to 21,739,131 shares of comm |
|
| April 3, 2019 |
Subject to completion, dated April 3, 2019 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-221837 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the U.S. Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to |
|
| April 3, 2019 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2019 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Comm |
|
| March 21, 2019 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2019 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 14, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2019 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 14, 2019 |
AVEO Reports Full Year 2018 Financial Results and Provides Business Update Exhibit 99.1 AVEO Reports Full Year 2018 Financial Results and Provides Business Update CAMBRIDGE, Mass. – March 14, 2019 – AVEO Oncology (NASDAQ: AVEO) today reported financial results for the full year ended December 31, 2018 and provided a business update. “The results of TIVO-3, presented in February at the 2019 ASCO GU Symposium, underscore a unique activity and tolerability profile among VEG |
|
| March 14, 2019 |
EXHIBIT 10.22 SEVERANCE AND CHANGE IN CONTROL AGREEMENT THIS SEVERANCE AND CHANGE IN CONTROL AGREEMENT (the “Agreement”), made this 13th day of March 2019 (the “Effective Date”), is entered into by AVEO Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 1 Broadway 14th Floor, Cambridge, MA 02142 (the “Company”), and Karuna Rubin (the “Employee”). WHEREAS, the Com |
|
| March 14, 2019 |
EXHIBIT 10.36 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. AGREEMENT Agreement (the “Agreement”), dated December 18, 2018 (the “Agreement Effective Date”), by and between Novartis International Pharmaceutical Ltd. (“Novartis”) and AVEO Pharmaceuticals, Inc. (“AVEO”). Novartis and AVEO are separately referred to |
|
| March 14, 2019 |
Offer Letter by and between the Registrant and Karuna Rubin dated June 16, 2015 AVEO Pharmaceuticals, Inc. 1 Broadway, 14th Floor Cambridge, MA 02142 p. 617.588.1960 EXHIBIT 10.21 June 16, 2015 Karuna Rubin [address] [address] Dear Karuna: It is with great pleasure that we extend you this offer of employment to join AVEO Pharmaceuticals. The following letter sets forth the proposed terms and conditions of your offer of employment. Position. Your position will be Senior Corpor |
|
| March 14, 2019 |
Subsidiaries of the Registrant EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Organization Percentage Ownership AVEO Pharma Limited United Kingdom 100% AVEO Securities Corporation Massachusetts 100% AVEO Pharma (Ireland) Limited Ireland 100% |
|
| March 14, 2019 |
AVEO / AVEO Pharmaceuticals, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2018 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34655 AVEO PHARMACE |
|
| March 1, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2019 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 15, 2019 |
EX-99.1 AVEO Overview February 2019 Exhibit 99.1 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may, |
|
| February 15, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2019 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 6, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2019 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 19, 2018 |
Entry into a Material Definitive Agreement 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2018 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 28, 2018 |
SC 13D/A 1 aveogeo418272.htm GROWTH EQUITY OPPORTUNITIES FUND IV, LLC - AVEO PHARMACEUTICALS, INC. - SCHEDULE 13D/A (AMEND. #3) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Aveo Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 053588109 (CUSIP Numb |
|
| November 9, 2018 |
AVEO Reports Third Quarter 2018 Financial Results and Provides Business Update Exhibit 99.1 AVEO Reports Third Quarter 2018 Financial Results and Provides Business Update CAMBRIDGE, Mass. – November 9, 2018 – AVEO Oncology (NASDAQ: AVEO) today reported financial results for the third quarter ended September 30, 2018 and provided a business update. “The recent announcement of positive topline results from the Phase 3 TIVO-3 study in renal cell carcinoma is transformative for |
|
| November 9, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2018 AVEO Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34655 04-3581650 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 9, 2018 |
AVEO / AVEO Pharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| November 5, 2018 |
EX-99.1 TIVO-3: Phase 3 Pivotal Trial of Tivozanib Meets Primary Endpoint of Improving Progression Free Survival in Renal Cell Carcinoma Exhibit 99.1 Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statement |
